Literature DB >> 9613625

Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters.

P O'Donnell1, A A Grace.   

Abstract

The absence of an animal model that accurately approximates schizophrenia limits current research into the pathophysiology of this disorder. Obviously, the cognitive disturbances associated with schizophrenia are difficult to evaluate in laboratory animals. Nonetheless, animal studies have provided insight into the anatomy and physiology of the brain systems that have been implicated in schizophrenia. These studies also suggest how brain systems may be involved in information processing in normal and pathological conditions. Thus, a careful assessment of the properties and functions of the brain regions suggested to be involved in schizophrenic symptoms has been a primary objective in several laboratories. In this review, we discuss the interactions among the brain regions implicated in schizophrenia--the ventral striatum, prefrontal cortex, hippocampus, and dopamine systems--and provide an integrative model linking altered function in these regions with specific clusters of symptoms of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613625     DOI: 10.1093/oxfordjournals.schbul.a033325

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  40 in total

1.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Authors:  A Abi-Dargham; J Rodenhiser; D Printz; Y Zea-Ponce; R Gil; L S Kegeles; R Weiss; T B Cooper; J J Mann; R L Van Heertum; J M Gorman; M Laruelle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Network synchrony in the nucleus accumbens in vivo.

Authors:  Y Goto; P O'Donnell
Journal:  J Neurosci       Date:  2001-06-15       Impact factor: 6.167

3.  Delayed mesolimbic system alteration in a developmental animal model of schizophrenia.

Authors:  Yukiori Goto; Patricio O'Donnell
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

4.  Disrupted activity in the hippocampal-accumbens circuit of type III neuregulin 1 mutant mice.

Authors:  Malcolm W Nason; Avishek Adhikari; Marjan Bozinoski; Joshua A Gordon; Lorna W Role
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

5.  Dopaminergic modulation of prefrontal cortical input to nucleus accumbens neurons in vivo.

Authors:  Anne Marie Brady; Patricio O'Donnell
Journal:  J Neurosci       Date:  2004-02-04       Impact factor: 6.167

6.  A subpopulation of neurons in the medial prefrontal cortex encodes emotional learning with burst and frequency codes through a dopamine D4 receptor-dependent basolateral amygdala input.

Authors:  Steven R Laviolette; Witold J Lipski; Anthony A Grace
Journal:  J Neurosci       Date:  2005-06-29       Impact factor: 6.167

7.  A naturalistic study of grey matter volume increase after early treatment in anti-psychotic naïve, newly diagnosed schizophrenia.

Authors:  Michelle Y Deng; Gráinne M McAlonan; Charlton Cheung; Cindy P Y Chiu; Chi W Law; Vinci Cheung; Pak C Sham; Eric Y H Chen; Siew E Chua
Journal:  Psychopharmacology (Berl)       Date:  2009-07-30       Impact factor: 4.530

8.  Antipsychotic drug-induced increases in ventral tegmental area dopamine neuron population activity via activation of the nucleus accumbens-ventral pallidum pathway.

Authors:  Ornella Valenti; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2009-09-15       Impact factor: 5.176

9.  Modulation of synaptic potentials and cell excitability by dendritic KIR and KAs channels in nucleus accumbens medium spiny neurons: a computational study.

Authors:  Jessy John; Rohit Manchanda
Journal:  J Biosci       Date:  2011-06       Impact factor: 1.826

10.  Critical role of the prefrontal cortex in the regulation of hippocampus-accumbens information flow.

Authors:  Pauline Belujon; Anthony A Grace
Journal:  J Neurosci       Date:  2008-09-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.